Enzo Biochem Inc.
527 Madison Avenue
New York,
NY 10022
United States - Map
Phone: 212-583-0100
Fax: 212-583-0150
Web Site: http://www.enzo.com
| Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. The Enzo Life Sciences segment manufactures, develops, and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers. It offers products applied in the fields of antibiotics, autophagy, cancer, cell cycle, cell death, cell signaling, cell trafficking, genomics/molecular biology, immunology, inflammation, lipid signaling, neurobiology, protein degradation, ROS/RNS, and stress/heat shock. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 30 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The Enzo Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene regulation for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem, Inc. sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, Belgium, and Germany. The company was founded in 1976 and is headquartered in New York, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Elazar Rabbani Ph.D., 65
Co-Founder, Chairman, Chief Exec. Officer and Sec. |
$
885.00K |
$
206.00K | Mr. Barry Weiner , 59
Co-Founder, Pres, Chief Financial Officer, Principal Accounting Officer, Treasurer |
$
703.00K |
$
206.00K | Mr. Shahram K. Rabbani , 57
Co-Founder |
$
678.00K |
$
206.00K | Dr. Carl W. Balezentis Ph.D., 51
Pres of Enzo Life Sciences Inc |
$
291.00K |
$
0 | Mr. Andrew R. Crescenzo CPA, 53
Sr. VP of Fin. |
$
266.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
